Cell population dynamics for the multi-step model. by Anshul Saini (11320669)

Reactions with significant changes in flux statistics between unconstrained and constrained simulations. by Chaitra Sarathy (11663427)

Results of XCOM and step velocity. by Saori Miyagishima (14593506)

Subjects:

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

BST2 overexpression decreased RSV multiplication. by Katherine Marougka (13015146)

<i>In vivo</i> voxel based morphometry identified a significant interaction between time and training. by Alexandra Badea (352052)

Parameter estimates of linear mixed effects models for juvenile <i>M</i>. <i>mercenaria</i>, juvenile <i>M</i>. <i>arenaria</i> and juvenile <i>A</i>. <i>islandica</i> proportional... by Teagan McMahon (20108036)

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)